Patterns of use of sildenafil among commercially insured adults in the united states: 1998–2002

ABSTRACT Sildenafil is increasingly being marketed to younger healthcare consumers. The purpose of this study was to profile sildenafil use in commercially insured, adult beneficiaries.

Annual ambulatory prescription claims data from 1998 to 2002, for a nationwide, random sample of over 5 million life-years of commercially insured adults (aged ≥18 y), were examined

retrospectively. The overall prevalence of sildenafil use increased from 0.8% (1998) to 1.4% (2002), an 84% increase. While the growth in use slowed in older males, use became more

pronounced in younger males and females and decreased in older females. The fastest growing segment of users was found to be males aged 18–45 y. The proportion of users who had two or more

claims for a medication that is suspected of inducing erectile dysfunction (ED) and/or a marker for a suspected ED-inducing disease decreased over the study period. Our findings suggest that

use may increase among younger male and female patients and those without an underlying etiologic reason for use. Access through your institution Buy or subscribe This is a preview of

subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only

$21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout

ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS BEYOND THE PRESCRIPTION:

TRENDS AND CHALLENGES IN ERECTILE DYSFUNCTION MEDICATIONS AMONG YOUNG ADULT MEN Article 03 June 2024 RISK FACTORS, DIAGNOSIS, AND LONG-TERM ERECTILE DYSFUNCTION OUTCOMES IN PRIAPISM: A

RETROSPECTIVE ANALYSIS OF 186 CASES FROM A SINGLE INSTITUTION Article Open access 22 April 2025 PATIENT OUT-OF-POCKET COSTS FOR GUIDELINE-RECOMMENDED TREATMENTS FOR ERECTILE DYSFUNCTION: A

MEDICARE COST MODELING ANALYSIS Article Open access 26 June 2024 REFERENCES * American Psychiatric Association. _Diagnostic and Statistical Manual of Mental Disorders_, 4th edn. American

Psychiatric Association: Washington, DC, 1994, pp 493–522. * Laumann EO, Paik A, Rosen RC . Sexual dysfunction in the United States: prevalence and predictors. _JAMA_ 1999; 281: 537–544.

Article  CAS  Google Scholar  * Ragucci KR, Culhane NS . Treatment of female sexual dysfunction. _Ann Pharmacother_ 2003; 37: 546–555. Article  CAS  Google Scholar  * Chew KK et al. Erectile

dysfunction in general medicine practice: prevalence and clinical correlates. _Int J Impot Res_ 2000; 12: 41–45. Article  CAS  Google Scholar  * Slag M et al. Impotence in medical clinic

outpatients. _JAMA_ 1983; 249: 1736–1740. Article  CAS  Google Scholar  * Benet AE, Melman A . The epidemiology of erectile dysfunction. _Urol Clin N Am_ 1995; 22: 699–709. CAS  Google

Scholar  * NIH Consensus Conference. Impotence: NIH Consensus Development Panel on Impotence. _JAMA_ 1993; 270: 83–90. * Gingell C et al. Guidance on the management of erectile dysfunction

in primary care. _Prescriber_ 1999; 5(Suppl): 1–19. Google Scholar  * Feldman HA et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study.

_J Urol_ 1994; 151: 54–61. Article  CAS  Google Scholar  * Kaiser FE et al. Impotence and aging: clinical and hormonal factors. _J Am Geriatr Soc_ 1988; 36: 511–519. Article  CAS  Google

Scholar  * Mulligan T, Katz PG . Why aged men become impotent. _Arch Intern Med_ 1989; 149: 1365–1366. Article  CAS  Google Scholar  * Hanash KA . Comparative results of goal oriented

therapy for erectile dysfunction. _J Urol_ 1997; 157: 2135–2138. Article  CAS  Google Scholar  * Jarow JP et al. Outcome analysis of goal directed therapy for impotence. _J Urol_ 1996; 155:

1609–1612. Article  CAS  Google Scholar  * Lamberg L . New drug for erectile dysfunction boon for many, ‘viagravation’ for some. _JAMA_ 1998; 280: 867–869. Article  CAS  Google Scholar  *

Viagra Package Insert. Available at: http://www.viagramd.com/pi/proPackInsert.asp. Accessed July 21, 2003. * Kaplan SA et al. Safety and efficacy of sildenafil in postmenopausal women with

sexual dysfunction. _Urology_ 1999; 53: 481–486. Article  CAS  Google Scholar  * Caruso S, Intelisano G, Lupo L, Agnello C . Premenopausal women affected by sexual arousal disorder treated

with sildenafil: a double-blind, cross-over, placebo-controlled trial. _Br J Obstet Gynaecol_ 2001; 108: 623–628. CAS  Google Scholar  * Rosen RC . Sildenafil: medical advance or media

event. _Lancet_ 1998; 351: 1599–1600. Article  CAS  Google Scholar  * Braun M, Klotz T, Mathers MJ . ‘Viagra Effect’ —influence of mass media on patient behavior. _Urol Int_ 2001; 66:

145–148. Article  CAS  Google Scholar  * Leland J . _Ideas and Trends: Big Pharma Ogles Yasgur's Farm_, The New York Times, 2001, July 29, Section 4 p 3. * Klein R, Sturm H . Viagra: a

success story for rationing? _Health Aff (Millwood)_ 2002; 21: 177–187. Article  Google Scholar  * Keith A . The economics of Viagra. _Health Aff (Millwood)_ 2000; 19: 147–157. Article  CAS

  Google Scholar  * Titlow K, Randel L, Clancy CM, Emanuel EJ . Drug coverage decisions: the role of dollars and values. _Health Aff (Millwood)_ 2000; 19: 240–247. Article  CAS  Google

Scholar  * Mitrany D . Lifestyle drugs: determining their value and who should pay. _Pharmacoeconomics_ 2001; 19: 441–448. Article  CAS  Google Scholar  * Rosenthal MB et al. Promotion of

prescription drugs to consumers. _N Engl J Med_ 2002; 346: 498–505. Article  Google Scholar  * Loyd L . _Pharmaceutical Firms take Fight for Impotence Drug Users to the Mat_, Philadelphia

Inquirer, 2003, July 6, p. E01. * Lim PH, Moorthy P, Benton KG . The clinical safety of Viagra. _Ann NY Acad Sci_ 2002; 962: 378–388. Article  CAS  Google Scholar  * Kloner RA . Viagra: what

every physician should know. _Ear Nose Throat J_ 1998; 77: 783–786. CAS  PubMed  Google Scholar  * Kloner RA, Jarow JP . Erectile dysfunction and sildenafil citrate and cardiologists. _Am J

Cardiol_ 1999; 83: 576–582, A7. Article  CAS  Google Scholar  * Harrold LR et al. The diffusion of a novel therapy into clinical practice: the case of sildenafil. _Arch Intern Med_ 2000;

160: 3401–3405. Article  CAS  Google Scholar  * First DataBank (Medi-Span). _Generic Product Identifier Number_. First DataBank (Medi-Span): Indianapolis, IN, 2001. * McLeod AL, McKenna CJ,

Northbridge DB . Myocardial infarction following the combined recreational use of Viagra and cannabis. _Clin Cardiol_ 2002; 25: 133–134. Article  CAS  Google Scholar  * Colfax GN et al. Drug

use and sexual risk behavior among gay and bisexual men who attend circuit parties: a venue-based comparison. _J Acquir Immune Defic Syndr_ 2001; 28: 373–379. Article  CAS  Google Scholar 

* Schwartz RK, Soumerai SB, Avorn J . Physician motivations for nonscientific drug prescribing. _Soc Sci Med_ 1989; 28: 577–582. Article  CAS  Google Scholar  * Ashworth M, Clement S, Wright

M . Demand, appropriateness and prescribing of ‘lifestyle drugs’: a consultation survey in general practice. _Fam Pract_ 2002; 19: 236–241. Article  Google Scholar  * Wilson ECF et al. The

cost to the United Kingdom National Health Service of managing erectile dysfunction: the impact of sildenafil and prescribing restrictions. _Pharmacoeconomics_ 2002; 20: 879–889. Article 

Google Scholar  * Maguire P . How direct to consumer advertising is putting the squeeze on physicians. Available at:

http://www.acponline.org/shell-cgi/printhappy.pl/journals/news/mar99/squeeze.htm. Accessed July 22, 2003. * Lewis RW . Epidemiology of erectile dysfunction. _Urol Clin N Am_ 2001; 28:

209–216. Article  CAS  Google Scholar  * McKinlay JB . The worldwide prevalence and epidemiology of erectile dysfunction. _Int J Impot Res_ 2000; 12(Suppl 4): S6–S11. Article  Google Scholar

  Download references ACKNOWLEDGEMENTS We express our appreciation to Dr Jagat Sheth for his assistance. This study was funded by Express Scripts, Inc. AUTHOR INFORMATION AUTHORS AND

AFFILIATIONS * Express Scripts, Inc., 13900 Riverport Dr. STL12N, Maryland Heights, Missouri, USA T Delate, V A Simmons & B R Motheral Authors * T Delate View author publications You can

also search for this author inPubMed Google Scholar * V A Simmons View author publications You can also search for this author inPubMed Google Scholar * B R Motheral View author

publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to T Delate. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE

CITE THIS ARTICLE Delate, T., Simmons, V. & Motheral, B. Patterns of use of sildenafil among commercially insured adults in the United States: 1998–2002. _Int J Impot Res_ 16, 313–318

(2004). https://doi.org/10.1038/sj.ijir.3901191 Download citation * Received: 21 August 2003 * Revised: 13 November 2003 * Accepted: 08 December 2003 * Published: 19 February 2004 * Issue

Date: 01 August 2004 * DOI: https://doi.org/10.1038/sj.ijir.3901191 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a

shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * sildenafil *

pharmacoepidemiology * advertising